tradingkey.logo

Evoke Pharma Inc

EVOK
10.660USD
0.000
Horarios del mercado ETCotizaciones retrasadas 15 min
15.91MCap. mercado
PérdidaP/E TTM

Más Datos de Evoke Pharma Inc Compañía

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.

Información de Evoke Pharma Inc

Símbolo de cotizaciónEVOK
Nombre de la empresaEvoke Pharma Inc
Fecha de salida a bolsaSep 25, 2013
Director ejecutivoMr. Matthew J. (Matt) D'Onofrio
Número de empleados3
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 25
Dirección420 Stevens Avenue
CiudadSOLANA BEACH
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal92075
Teléfono18583451494
Sitio Webhttps://evokepharma.com/
Símbolo de cotizaciónEVOK
Fecha de salida a bolsaSep 25, 2013
Director ejecutivoMr. Matthew J. (Matt) D'Onofrio

Ejecutivos de Evoke Pharma Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Matthew J. (Matt) D'Onofrio
Mr. Matthew J. (Matt) D'Onofrio
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
9.82K
+15.50%
Mr. Cam L. Garner
Mr. Cam L. Garner
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
2.33K
-0.04%
Dr. Malcolm R. Hill, Pharm.D.
Dr. Malcolm R. Hill, Pharm.D.
Independent Director
Independent Director
133.00
-0.75%
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
Independent Director
Independent Director
27.00
-3.57%
Mr. Greg Pyszcymuka
Mr. Greg Pyszcymuka
Independent Director
Independent Director
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--
Dr. Marilyn R. Carlson, M.D.
Dr. Marilyn R. Carlson, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Benjamin C. (Ben) Smeal
Mr. Benjamin C. (Ben) Smeal
Independent Director
Independent Director
--
--
Mr. Daniel Kontoh-Boateng
Mr. Daniel Kontoh-Boateng
Investor Contact
Investor Contact
--
--
Ms. Vickie W. Reed
Ms. Vickie W. Reed
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Matthew J. (Matt) D'Onofrio
Mr. Matthew J. (Matt) D'Onofrio
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
9.82K
+15.50%
Mr. Cam L. Garner
Mr. Cam L. Garner
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
2.33K
-0.04%
Dr. Malcolm R. Hill, Pharm.D.
Dr. Malcolm R. Hill, Pharm.D.
Independent Director
Independent Director
133.00
-0.75%
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
Independent Director
Independent Director
27.00
-3.57%
Mr. Greg Pyszcymuka
Mr. Greg Pyszcymuka
Independent Director
Independent Director
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--

Desglose de ingresos

FY2025Q2
FY2025Q1
FY2024
FY2024Q1
FY2023
FY2022
FY2021
FY2020
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
3.75M
0.00%
Por negocio
Por región
Sin datos

Estadísticas de accionistas

Actualizado: lun., 3 de nov
Actualizado: lun., 3 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Morgan Stanley Smith Barney LLC
10.51%
Nantahala Capital Management, LLC
9.51%
National Wealth Management Group, LLC
5.14%
Bleichroeder LP
4.41%
Citadel Advisors LLC
0.80%
Otro
69.63%
Accionistas
Accionistas
Proporción
Morgan Stanley Smith Barney LLC
10.51%
Nantahala Capital Management, LLC
9.51%
National Wealth Management Group, LLC
5.14%
Bleichroeder LP
4.41%
Citadel Advisors LLC
0.80%
Otro
69.63%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
20.62%
Hedge Fund
10.44%
Individual Investor
1.28%
Investment Advisor/Hedge Fund
0.50%
Otro
67.16%

Participación institucional

Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
26
491.93K
31.57%
+96.05K
2025Q2
34
272.65K
18.26%
-174.03K
2025Q1
37
273.02K
18.29%
-164.20K
2024Q4
38
286.68K
19.29%
-150.95K
2024Q3
39
276.54K
27.87%
-57.30K
2024Q2
39
330.88K
325.68%
-1.95K
2024Q1
46
331.84K
45.81%
+48.22K
2023Q4
42
12.65K
4.52%
-4.41K
2023Q3
46
12.52K
4.50%
-16.16K
2023Q2
47
11.87K
4.27%
-16.69K
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Morgan Stanley Smith Barney LLC
163.72K
10.51%
+163.65K
+255709.38%
Aug 31, 2025
Nantahala Capital Management, LLC
148.15K
9.51%
--
--
Jun 30, 2025
Bleichroeder LP
68.75K
4.41%
--
--
Jun 30, 2025
Citadel Advisors LLC
12.54K
0.8%
-12.26K
-49.43%
Jun 30, 2025
D'Onofrio (Matthew J)
9.82K
0.63%
+1.32K
+15.50%
Mar 24, 2025
The Vanguard Group, Inc.
1.71K
0.11%
--
--
Aug 31, 2025
Geode Capital Management, L.L.C.
7.86K
0.5%
-19.00
-0.24%
Aug 31, 2025
Kowieski (Mark A.)
4.92K
0.32%
+4.92K
--
Mar 24, 2025
Gonyer (David A)
2.36K
0.15%
-1.00
-0.04%
Mar 24, 2025
Ver más

ETFs relacionados

Actualizado: dom., 2 de nov
Actualizado: dom., 2 de nov
Nombre
Proporción
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Tipo
Relación
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
Fecha
Tipo
Relación
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
KeyAI